EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Treatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation

Musa Khaitov iD, Alexandra Nikonova iD, Ilya Kofiadi, Igor Shilovskiy, Valeriy Smirnov, Olga Elisytina, Artem Maerle, Artem Shatilov, Anastasia Shatilova, Sergey Andreev, Ilya Sergeev, Dmitry Trofimov und 26 weitere

Allergy · 2023-06 · 78 (6) · 1639-1653

DOI: 10.1111/all.15663 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 14.02.2023. Verfasst von Musa Khaitov und 37 weiteren Autor:innen. Beteiligte Einrichtung: National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia. Hauptthemen laut MEDLINE: COVID-19, Dendrimers. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation MIR 19® (siR‐7‐EM/KK‐46) targeting a conserved sequence in known SARS‐CoV‐2 variants for treatment of COVID‐19.

Methods

We conducted an open‐label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR‐7‐EM/KK‐46 (3.7 mg and 11.1 mg/day: low and high dose, respectively) in comparison with standard etiotropic drug treatment (control group) in patients hospitalized with moderate COVID‐19 ( N = 52 for each group). The primary endpoint was the time to clinical improvement according to predefined criteria within 14 days of randomization.

Results

Patients from the low‐dose group achieved the primary endpoint defined by simultaneous achievement of relief of fever, normalization of respiratory rate, reduction of coughing, and oxygen saturation of >95% for 48 h significantly earlier (median 6 days; 95% confidence interval [CI]: 5–7, HR 1.75, p = .0005) than patients from the control group (8 days; 95% CI: 7–10). No significant clinical efficacy was observed for the high‐dose group. Adverse events were reported in 26 (50.00%), 25 (48.08%), and 28 (53.85%) patients from the low‐, high‐dose and control group, respectively. None of them were associated with siR‐7‐EM/KK‐46. Conclusions siR‐7‐EM/KK‐46, a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID‐19 compared to standard therapy in a randomized controlled trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19DendrimersHumansSARS-CoV-2RNA, Small InterferingTreatment OutcomePeptides

Stichwörter der Autor:innen

SARS-CoV-2clinical trialefficacysafetysiRNA

Substanzen

DendrimersRNA, Small InterferingPeptides

Autor:innen und Institutionen

  • National Research Center (NRC) Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.
  • Pirogov Russian National Research Medical University, Moscow, Russia.
  • RUDN University, Moscow, Russia.
  • I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Federal State Unitary Enterprise "The Saint Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations" of Federal Medical and Biologic Agency (FSUE S…
  • North-West District Scientific and Clinical Center named after L.G. Sokolov Federal Medical and Biological Agency, St. Petersburg, Russia.

ORCID-Profile: Musa Khaitov, Alexandra Nikonova, Nikita Savelev, Rudolf Valenta

Zitieren

APA

Khaitov, M., Nikonova, A., Kofiadi, I., Shilovskiy, I., Smirnov, V., Elisytina, O., Maerle, A., Shatilov, A., Shatilova, A., Andreev, S., Sergeev, I., Trofimov, D., Latysheva, T., Ilyna, N., Martynov, A., Rabdano, S., Ruzanova, E., Savelev, N., Pletiukhina, I., …, & Skvortsova, V. (2023). Treatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation. Allergy, 78(6), 1639-1653. https://doi.org/10.1111/all.15663

Vancouver

Khaitov M, Nikonova A, Kofiadi I, Shilovskiy I, Smirnov V, Elisytina O, et al. Treatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation. Allergy. 2023;78(6):1639-1653. doi:10.1111/all.15663

BibTeX
@article{Khaitov2023,
  author = {Khaitov, Musa and Nikonova, Alexandra and Kofiadi, Ilya and Shilovskiy, Igor and Smirnov, Valeriy and Elisytina, Olga and Maerle, Artem and Shatilov, Artem and Shatilova, Anastasia and Andreev, Sergey and Sergeev, Ilya and Trofimov, Dmitry and Latysheva, Tatyana and Ilyna, Natalia and Martynov, Alexander and Rabdano, Sevastyan and Ruzanova, Ellina and Savelev, Nikita and Pletiukhina, Iuliia and Safi, Ariana and Ratnikov, Vyacheslav and Gorelov, Viktor and Kaschenko, Viktor and Kucherenko, Natalya and Umarova, Irina and Moskaleva, Svetlana and Fabrichnikov, Sergei and Zuev, Oleg and Pavlov, Nikolai and Kruchko, Daria and Berzin, Igor and Goryachev, Dmitriy and Merkulov, Vadim and Shipulin, German and Udin, Sergey and Trukhin, Victor and Valenta, Rudolf and Skvortsova, Veronica},
  title = {Treatment of COVID ‐19 patients with a SARS‐CoV ‐2‐specific siRNA ‐peptide dendrimer formulation},
  journal = {Allergy},
  year = {2023},
  volume = {78},
  number = {6},
  pages = {1639--1653},
  doi = {10.1111/all.15663}
}
Kostenlos starten →